Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
2.760
-0.110 (-3.83%)
Feb 27, 2026, 4:00 PM EST - Market closed
Prelude Therapeutics Market Cap
Prelude Therapeutics has a market cap or net worth of $227.42 million as of February 27, 2026. Its market cap has increased by 230.86% in one year.
Market Cap
227.42M
Enterprise Value
190.31M
1-Year Change
230.86%
Ranking
Category
Stock Price
$2.76
Market Cap Chart
Since the IPO on September 25, 2020, Prelude Therapeutics's market cap has decreased from $806.64M to $227.42M, a decrease of -71.81%. That is a compound annual growth rate of -20.81%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 27, 2026 | 227.42M | -4.83% |
| Dec 31, 2025 | 238.95M | 147.03% |
| Dec 31, 2024 | 96.73M | -70.04% |
| Dec 29, 2023 | 322.85M | 12.32% |
| Dec 30, 2022 | 287.43M | -50.22% |
| Dec 31, 2021 | 577.35M | -80.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Sol-Gel Technologies | 248.35M |
| Opus Genetics | 247.58M |
| Orchestra BioMed Holdings | 244.49M |
| Protalix BioTherapeutics | 242.07M |
| Crescent Biopharma | 237.92M |
| Cibus | 237.80M |
| Humacyte | 237.39M |
| Nuvectis Pharma | 236.84M |